A study of Abl Tyrosine Kinase Inhibitor K0706-potential disease modifying trial (H-44521)

A 44 Week, Double Blind Placebo controlled study of Abl Tyrosine Kinase Inhibitor K0706-potential disease modifying trial.

Seeking progress to potentially help slow disease progression for people with early-stage Parkinson's Disease.  This is a clinical research study evaluating a once-daily, oral investigational drug for people with early-stage PD.  The investigational drug is designed to block a specific enzyme called "Abl".  Research has shown that overactivation of Abl may play a role in PD progression.  Therefore, by limiting or blocking Abl, it may be possible to help to slow PD progression.  You may be eligible to participate if:

• you are 50 years of age or older
• have been diagnosed with PD with symptoms beginning in the past three years
• have not taken PD medications for more than 30 days at any time in the past